Redeye comments on FluoGuide’s Q3 2025 report. The company has posted a busy news flow in recent months, announcing positive FDA feedback, an interim LGG/meningioma readout, a directed share issue, a new member of management, and a collaboration with Zeiss. We judge the share’s next significant trigger will be the company’s phase II HNC interim readout in H1 2026e, which could pave the way to pivotal trials in this indication.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/